Skip to main content

Table 2 Follow-up variables; immunosuppression, outcome and cause of graft loss

From: Induction with interleukin-2 antagonist for transplantation of kidneys from older deceased donors: an observational study

 

IL-2 plus

IL-2 minus

P

 

(N=149)

(N=83)

 

Immunosuppression at 10 weeks

   

CsA

99 (67%)

60 (77%)

ns

Tacrolimus

31 (21%)

10 (13%)

ns

mTOR inhibitor

14 (10%)

9 (12%)

ns

CsA dose (mg/day)

250.5 ± 73.5

255.4 ± 87.8

ns

CsA C0 concentration

151.4 ± 56.5

183.3 ± 85.6

0.01

Tacrolimus dose (mg/day)

5.65 ± 2.95

8.70 ± 4.64

ns

Tacrolimus concentration

7.3 ± 2.1

9.2 ± 2.3

ns

Prednisolone dose (mg/day)

12,4 ± 5.6

13.6 ± 5.6

ns

MMF (mg/day)

1678.1 ± 402.9

1750.0 ± 619.9

ns

Outcome

   

Delayed graft function

53 (36%)

29 (35%)

ns

Acute rejection 90 days post transplant

29 (20%)

34 (41%)

0.001

Acute rejection 180 days post transplant

38 (26%)

35 (42%)

0.01

Steroid-resistant rejection (biopsy proven)

5 (3%)

18 (22%)

< 0.001

C4D positive biopsy

4 (5%)

4 (3%)

ns

Cause of graft loss

   

Death with functioning graft

32 (22%)

24 (29%)

ns

Primary non-function

0

6 (7%)

0.002

Primary vascular thrombosis

3 (2%)

2 (2%)

ns

Rejection

5 (3%)

10 (12%)

0.02

Recurrent primary disease

0

1 (1%)

ns

Urological complications

1 (1%)

0

ns

De novo glomerulonephritis

1 (1%)

0

ns

Insufficient graft function

0

2 (2%)

ns

Not specified

2 (1%)

2 (2%)

ns